Re: Living Cell Technologies Clinical Trial Authorized by NZ Government

[ Follow-Ups ] [ Post Followup ] [ The Islet Foundation Public Message Forum ]

Posted by Financial24 on 12:23:51 2009/06/24

In Reply to: Re: Hopes For Start To Pig Cell Implant Trials In Two Months posted by Voxy

Your browser does not support inline frames, or it has been configured incorrectly. If page does not display on your browser, please <a href="http://www.financial24.org/economy/living-cell-technologies-diabetes-clinical-trial-authorized-by-new-zealand-government/">CLICK HERE</a>. Living Cell Technologies Diabetes Clinical Trial Authorized by New Zea... | Financial 24 GS_googleAddAdSenseService("ca-pub-6606081569437601"); GS_googleEnableAllServices(); GA_googleAddSlot("ca-pub-6606081569437601", "financial24"); GA_googleAddSlot("ca-pub-6606081569437601", "top_financial"); GA_googleFetchAds(); Living Cell Technologies Diabetes Clinical Trial Authorized by New Zea SYDNEY and AUCKLAND, New Zealand, June 24 /PRNewswire/ Living Cell Technologies Limited tod... Wednesday 24 June 2009 economy Living Cell Technologies Diabetes Clinical Trial Authorized by New Zealand Government GA_googleFillSlot("financial24"); 3 SYDNEY and AUCKLAND, New Zealand, June 24 /PRNewswire/ Living Cell Technologies Limited today announced that the New Zealand Minister of Health, the Honourable Tony Ryall, has authorized LCT's New Zealand Phase I/IIa clinical trial of DIABECELL for insulin dependent diabetes . The authorization confirms the conditions announced on 19 June 2009 . One condition of the new authorization limits participation in the trial to patients with poorly controlled diabetes . The remaining conditions are procedural rather than substantive in nature and LCT and the Middlemore Hospital clinical team conducting the trial, have requested the Regional Ethics Committee formally accept the changes required by the Minister . LCT CEO Dr Paul Tan said: We are pleased that the conditions have been finalized and LCT looks forward to commencing the trial within the next two months with the acceptance of the changes by the Ethics Committee . Professor Bob Elliott, LCT Founder and Medical Director added: The New Zealand diabetes trial is another major milestone for LCT . With two diabetes patients not requiring insulin following implants with encapsulated pig islet cells in our first study in Russia, we expect to see further benefit in more patients as we use higher doses of DIABECELL in the New Zealand trial . LCTs Phase I/IIa clinical trial in Russia started with a low dose of DIABECELL . In May 2009 LCT reported preliminary data showing sustained long term clinical benefit in patients treated with the DIABECELL implant with no remarkable adverse events . Remarkably, two of seven patients given implants are now off insulin injections . The New Zealand trial allows LCT to extend its Phase I/IIa clinical data with eight patients, four of whom are to receive double the initial dose used in Russia followed by four patients to receive triple the dose . Dr John Baker, Clinical Director and Diabetes Physician at Middlemore Hospital, Auckland, who will be conducting the trial said, There are many patients with poorly controlled diabetes who would qualify for this trial . DIABECELL is designed to normalize blood glucose levels in type 1 diabetes sufferers . DIABECELL comprises encapsulated porcine insulin-producing cells which can be administered without the need to use immunosuppressive drugs . Type 1 diabetes occurs when the body's own immune system destroys the insulin-producing cells of the pancreas . Five to 10 percent of the more than 200 million diabetics worldwide have insulin dependent type 1 diabetes . Type 1 diabetes is associated with kidney failure, blindness, nerve damage, life-threatening cardiovascular disease and limb amputations . Current treatment options include multiple daily injections of insulin . For further information: www.lctglobal.com . CONTACT: Dr . Paul Tan Chief Executive Officer Mob: +021-608-784 Tel: +64-9-276-2690 ptan@lctglobal.com Mr John Cowan Finance&Administration Manager Tel: +64-9-276-2690 jcowan@lctglobal.com Prof . Bob Elliott Medical Director Mob: +64-27-292-4177 Tel:+64-9-276-2690 relliott@lctglobal.com Paul Dekkers Investor and Media Relations Tel: +612-9237-2800 pdekkers@bcg.com.au Living Cell Technologies Dr . Paul Tan, Chief Executive Officer, Mob: +021-608-784 , Tel: +64-9-276-2690, or ptan@lctglobal.com, Mr . John Cowan, Finance&Administration Manager, Tel: +64-9-276-2690, or jcowan@lctglobal.com, Prof . Bob Elliott, Medical Director, Mob: +64-27-292-4177, Tel: +64-9-276-2690, or relliott@lctglobal.com, all of Living Cell Technologies; Paul Dekkers, Investor and Media Relations, Tel: +1-612-9237-2800, or pdekkers@bcg.com.au, for Living Cell Technologies Posted by economy 7 hours ago Living Cell Technologies ... Comments to Living Cell Technologies Diabetes Clinical Trial A Log in to comment or register here . Login Username: Password: Remember: Forgotten Password | Register Advanced Search Submit a New Story online 28 Top Today 4 Live Nation Expands Global... 4 Plan the Menu for Your Sum... 4 COPsync, Inc. Sees Rise in... 4 Interstate Hotels & Resort... 4 Activist funds ditch Japan... Financial News 3 Jim Beam® Bourbon Toasts t... 2 China Sun Group High-Tech ... 3 Sherritt, partners arrange... 2 Russian, Japanese firms ma... 4 National Business Group on... Copyright 2008-2009 Financial 24 | RSS Feeds | | Privacy | v. 3.62 var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); var pageTracker = _gat._getTracker("UA-1984886-1"); pageTracker._trackPageview();

Click here to visit inline page

Follow Ups:

Post a Followup

[ Follow Ups ] [ Post Followup ] [ The Islet Foundation Public Message Forum ]

Name:
E-Mail: (Optional)
Subject:
Comments:
Link URL: (Optional)
Link Title:
Image URL: (Optional)